USFWS rejects PETA petition on macaques
Analysis based on 10 articles · First reported Jul 14, 2026 · Last updated Jul 14, 2026
The decision removes a potential regulatory barrier for biomedical research using long-tailed macaques, supporting the pharmaceutical and biotechnology industries. No significant market impact is expected as the ruling maintains the status quo.
On July 14, 2026, the U.S. Fish and Wildlife Service (USFWS) for the second time rejected a petition from People for the Ethical Treatment of Animals (PETA) and other activist groups to list long-tailed macaque monkeys under the Endangered Species Act. USFWS determined the petition did not present substantial scientific information warranting further review. The National Association for Biomedical Research (NABR) commended the decision, stating that activist groups attempted to weaponize environmental processes to hinder medical research. Long-tailed macaques are crucial for biomedical research due to their physiological similarities to humans, contributing to advances in regenerative medicine, immunology, cancer, vaccine development, and pharmacology. The United States — National Institutes of Health (NIH) recently published a review confirming their importance.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard